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ISSObjective: Evaluations of CD4 cell count and other prognostic factors on the survival of
HIV patients in sub-Saharan Africa are extremely limited. Funders have been reticent to
recommend earlier initiation of treatment. We aimed to examine the effect of baseline
CD4 cell count on mortality using data from HIV patients receiving combination
antiretroviral therapy (cART) in Uganda.
Design: Observational study of patients aged at least 14 years enrolled in 10 clinics
across Uganda for which The AIDS Support Organization (TASO) has data.
Methods: CD4 cell count was stratified into categories (<50, 50–99, 100–149, 150–
199, 200–249, 250–299, 300 cells/ml) and Cox proportional hazards regression was
used to model the associations between CD4 cell count and mortality.
Results: A total of 22 315 patients were included. 1498 patients died during follow-up
(6.7%) and 1433 (6.4%) of patients were lost to follow-up. Crude mortality rates (CMRs)
ranged from 53.8 per 1000 patient-years [95% confidence interval (CI) 48.8–58.8]
among those with CD4 cell counts of less than 50, to 15.7, (95% CI 12.1–19.3) among
those with at least 300 cells/ml. Relative to a baseline CD4 cell count of less than
50cells/ml, the risk of mortality was 0.75 (95%CI 0.65–0.88), 0.60 (95%CI 0.51–0.70),
0.43 (0.37–0.50), and 0.41 (0.33–0.51) for those with baseline CD4 cell counts of
50–99, 100–149, 150–249, and 250 cells/ml, respectively.
Conclusion: Earlier initiation of cART is associated with increased survival benefits
over deferred treatment.  2011 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2011, 25:851–855Keywords: antiretroviral therapy, CD4, HIV, mortality, sub-Saharan Africa,
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852 AIDS 2011, Vol 25 No 6Organization (WHO) recommend that asymptomatic
patients initiate cART at CD4 cell count 350 cells/ml
or less [7], whereas the International AIDS Society
recommends that such patients initiate cARTeven earlier,
at CD4 cell count 500 cells/ml or less [8]. Current
guidance is based upon discordant evidence from wealthy
settings [9,10] and a single small randomized trial [11].
However, there is concern that resource limitations in
sub-Saharan Africa may prevent many health services
from managing the increased workload of earlier
initiation, and some international donors are reluctant
to support initiation of cART at CD4 cell counts higher
than 200 cells/ml [12].
Evaluations of CD4 cell count and other prognostic
factors on the survival of HIV patients in sub-Saharan
Africa are typically limited by small sample sizes and the
relative homogeneity of low CD4 cell counts among
patients starting cART [13–15]. Using data from a large
observational cohort of HIV patients receiving cART in
Uganda, our present study is the largest to examine the
effect of baseline CD4 cell count on mortality in sub-
Saharan Africa.
Methods
We used data from The AIDS Support Organization
(TASO) in Uganda. The program and data collection
process have been published previously [6,16]. Briefly,
patients aged at least 14 years who initiated cART at
TASO clinics in Uganda between 1 January 2000 and
1 February 2010 were included in this study. These patients
were followed until either the time of death or the end of
the study period (1 February 2010). For each patient, we
recorded age at the start of cART (years), sex, baseline CD4
cell count (<50, 50–99, 100–149, 150–249, 250–299,
and 300 cells/ml), WHO clinical disease stage (I, II, III,
IV), loss to follow-up (defined as a 3-month untraceable
absence from a clinic), year cART started, date last seen for
care, and when applicable, date of death. Patient adherence
to cART was defined as at least 95% or below 95%
and determined by a composite of pharmacy refill records,
3-day self-report, and drug possession ratio.
Analyses
We assessed survival according to CD4 status at baseline,
in categories of below 50, 50–99, 100–149, 150–199,
200–249, 250–299, and at least 300 cells/ml. We also
examined the Ugandan guidance on initiation of cART
before and after CD4 depletion at 250 cells/ml [17].
Survival distributions by CD4 cell count were estimated
using Kaplan–Meier methods and compared using the
log-rank test. These analyses were conducted for the
overall cohort and for those with 12 or more months of
follow-up. Patients lost to follow-up were censored at the
date when they were last seen, and patients alive at the
date when the study ended were censored at this date. We
applied a weighted analysis whereby 30% of patients lost
to follow-up were assumed dead, weighted by baselinepyright © Lippincott Williams & Wilkins. UnauthoCD4, age and male sex [16,18]. Survival times were
expressed in months. Unadjusted and adjusted Cox
proportional hazards regression [19] was conducted in
order to quantify the effect of CD4 cell count on survival,
adjusting for age, sex, and WHO clinical disease stage.
This analysis included point and confidence interval (CI)
estimates for the hazard ratios of death for each factor.
Hazard proportionality was assessed by analysis of scaled
Schoenfeld residuals. To account for missing baseline
CD4 cell counts we also conducted our analyses using the
multiple imputation method [20]. All significance tests
were two-sided with a P value of less than 0.05 considered
significant. All analyses were conducted using SAS
version 8 (SAS Institute, Cary, North Carolina, USA).
Institutional review
Approval to conduct this study was received from the
administrative headquarters ethics board of TASO
Uganda, and the Research Ethics Boards of the
University of Ottawa and the University of British
Columbia in Canada.Results
Characteristics of included population
We included 22 315 individuals at least 14 years of age who
initiated cART at TASO clinics in Uganda between 2004
and2010.Patientswere followed for a medianof 31months
[interquartile range (IQR)19–45].Web-appendixTable1,
http://links.lww.com/QAD/A122 shows the demo-
graphic and clinical characteristics of patients. The median
ageamongpatientswas37years (IQR31–43years), andthe
majority (69.4%) of patients were women. The median
CD4 cell count at cART initiation was 142 cells/ml (IQR
70–206 cells/ml) (72.5% initiated cART with a CD4 cell
count <200 cells/ml). A higher percentage of patients
(58.1%) started cARTwith a WHO disease stageof either II
or III. Adherence was high among patients, with 85.8%
maintaining at least 95% adherence.
Mortality
One thousand, four hundred and ninety-eight (6.7%)
patients died during follow-up and 1433 (6.4%) of
patients were lost to follow-up. Web-appendix Table 2,
http://links.lww.com/QAD/A122 shows the crude
mortality rates by baseline CD4 cell count. Rates are
presented overall and for the first year after cART
initiation and subsequent years combined. The highest
death rates were observed among patients initiating cART
with a CD4 cell count below 50 cells/ml. Death rates
were also highest within the first year of cART initiation.
Of note, as baseline CD4 cell count decreased, the death
rate generally increased.
When we applied the Ugandan criteria for initiation,
those patients who initiated cART were in the CD4 cellrized reproduction of this article is prohibited.
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Fig. 1. Kaplan–Meier estimates for the probability of survi-
val by CD4 strata (0–49, 50–99, 100–149, 150–199, 200–
249, 250–299, >–300 cells/ml).count categories below 250 and at least 250 cells/ml. The
estimated probability of survival after 12 months of
follow-up was 94.2% (95% CI 93.9–94.5) for patients
who initiated cART with a CD4 cell count less than
250 cells/ml, and 97.4 (95% CI 96.9–97.9) for patients
who initiated cART with a CD4 cell count at least
250 cells/ml. By 36 months, this was 92.3 (95% CI 91.9–
92.7) and 96.2 (95% CI 95.4–97.0). We observed a
significant difference between the CD4 cell count
categories over time (log-rank test, P< 0.001). When
we restricted the analysis to only patients with 12 or moreopyright © Lippincott Williams & Wilkins. Unauth
Table 1. Unadjusted and adjusted Cox proportional hazard models of time
Variable
Unadju
ratio (95
in
Age (continuous) (per decade increase) 1.08 (
Age (categorical) 14–19 1.00 (
20–29 0.81 (
30–39 0.82 (
40–49 0.78 (
50 1.06 (
Sex Male 1.54 (
CD4 cell count (cells/ml)
(continuous)
(per 100 cells increase) 0.63 (
CD4 cell count (cells/ml)
(categorical)
<50 1.00 (
50–99 0.76 (
100–149 0.56 (
150–249 0.37 (
250 0.32 (
WHO clinical disease stage Stage I 1.00 (
Stage II 1.05 (
Stage III 2.28 (
Stage IV 4.49 (
Missing 1.97 (
Year cART started (continuous) (per year increase) 0.70 (months of follow-up, a significant difference was main-
tained between the CD4 cell count categories (log-rank
test, P¼ 0.02).
Figure 1 shows the Kaplan–Meier survival estimates for
patients who initiated cART in the CD4 cell count
categories below 50, 50–99, 100–149, 150–199, 200–
249, 250–299, and at least 300 cells/ml. We observed a
significant difference between the CD4 cell count
categories over time (log-rank test, P< 0.001). When
we considered only patients with 12 or more months
of follow-up, a significant difference was also observed
between the CD4 cell count categories (log-rank test,
P< 0.001).
Regression analyses
Table 1 shows the results of the unadjusted and adjusted
Cox proportional hazards models of time to death. The
adjusted model indicated that the risk of mortality
increased significantly with decreasing CD4 cell count,
after adjusting for sex, WHO disease stage, and year of
cART initiation. Relative to a baseline CD4 cell count of
below 50 cells/ml, the risk of mortality was 0.75 (95% CI
0.65–0.88), 0.60 (95% CI 0.51–0.70), 0.43 (0.37–0.50),
and 0.41 (0.33–0.51) for those with baseline CD4 cell
counts of 50–99, 100–149, 150–249, and at least
250 cells/ml, respectively. Using the multiple imputation
method to account for missing baseline CD4 cell count
values, we found that the risk of mortality was
comparable: relative to a baseline CD4 cell count of
less than 50 cells/ml, the risk of mortality was 0.66 (95%
CI 0.57–0.76), 0.56 (95% CI 0.49–0.65), 0.44 (0.39–
0.49), and 0.44 (0.37–0.51) for those with baseline CD4
cell counts of 50–99, 100–149, 150–249, and at least
250 cells/ml.orized reproduction of this article is prohibited.
to death among patients initiating cART at TASO clinics in Uganda.
sted hazard
% confidence
terval) P value
Adjusted hazard
ratio (95% confidence
interval) P value
1.03–1.14) 0.004
–) 1.00 (–)
0.54–1.21) 0.301 0.83 (0.56–1.25) 0.383
0.55–1.21) 0.312 0.79 (0.53–1.16) 0.227
0.53–1.16) 0.225 0.73 (0.49–1.09) 0.128
0.71–1.60) 0.773 1.05 (0.69–1.57) 0.833
1.39–1.71) <0.001 1.48 (1.33–1.65) <0.001
0.59–0.67) <0.001
–) 1.00 (–)
0.66–0.88) <0.001 0.75 (0.65–0.88) <0.001
0.48–0.66) <0.001 0.60 (0.51–0.70) <0.001
0.32–0.43) <0.001 0.43 (0.37–0.50) <0.001
0.26–0.40) <0.001 0.41 (0.33–0.51) <0.001
–) 1.00 (–)
0.65–1.69) 0.845 1.24 (0.77–1.99) 0.382
1.42–3.65) <0.001 2.21 (1.37–3.54) 0.001
2.77–7.29) <0.001 4.71 (2.90–7.67) <0.001
1.23–3.15) 0.005 1.39 (0.87–2.22) 0.174
0.67–0.73) <0.001 0.69 (0.66–0.72) <0.001
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The study is the largest cohort study to examine the effect
of baseline CD4 cell counts on mortality in sub-Saharan
Africa. The results of this study clearly indicate that CD4
cell count is an important prognostic factor in HIV patients
on cART in Uganda. Specifically, this study found that
initiating cART with low CD4 cell count levels is
significantly associated with reduced survival time.
There are several features of this study that should be
highlighted. Although many programs in Africa are
affected by major loss to follow-up [21], TASO employs
a specific mobile team on motorcycles that consistently
track patients, thereby reducing overall loss to follow-up.
Although loss to follow-up is low in TASO programs,
compared with other sub-Saharan sites, we found that
about 6.4% of patients were lost once they initiated cART.
In a previous analysis, we found that about 26% of eligible
patients at baseline will not initiate cART and are lost to
follow-up prior to initiation, a third of whom were dead
[16]. We aimed to reduce any bias associated with lost
patients by applying a sensitivity analysis that assumes that
30% of those patients were deceased, based on findings
from our previous tracking study and a similar analysis at a
relevant local Ugandan setting [16,18]. Additionally,
monitoring and adherence counseling at TASO is superior
to that found in more developed settings, as adherence
counselors and database managers are employed at each
TASO clinical site. From the early years of the AIDS
epidemic in Uganda TASO has been involved with peer
support groups and psychosocial support.
We note that 3817 (17.1%) patients were missing baseline
CD4 cell count data. We examined the effect of this using
sensitivity analysis with multiple imputation. The absence
of complete CD4 cell count data is a reflection of the
constrained resources and diverse settings in Uganda and
has been demonstrated in other resource-constrained
settings [22]. Additionally, routine patient data on HIV
viral load or antiretroviral resistance testing are not
available at TASO. Therefore, it was not possible to
understand the impact of these factors on mortality
among patients at TASO. Furthermore, since this is an
observational study, conclusions about causality should
not be made. As with all observational studies, although
we adjusted our analyses for several demographic and
clinical factors, unmeasured differences may exist among
the study population.
Our study examined baseline CD4 levels as a predictor of
mortality and found consistent effects demonstrating
lower CD4 status is associated with increased mortality. It
is important to emphasize that the optimal time for
initiation of therapy cannot be determined from this
work. We demonstrate that decreased CD4 status at
treatment baseline is a strong predictor of mortality.
Differences in treatment effectiveness may differ when apyright © Lippincott Williams & Wilkins. UnauthoCD4 cell count is at high levels. Further, our study did not
account for lead-time bias, that is, the number of patients
who may have died prior to accessing therapy at any CD4
category [10]. It is possible, though unlikely, that any
patients dying prior to treatment would offset our study
findings.
Uganda is frequently cited as a leader in the response to
HIV/AIDS. In the context of improving access to
treatment, Uganda has issued guidance that patients
initiate at a CD4 cell count 250 cells or less, and will soon
strive to increase this to 300 cells. Although these
thresholds are arbitrary, they are based on the efforts of the
Ministry of Health to be progressive in achieving
improved health. Any increase in CD4 access appears
to offer reduced mortality compared to late initiation.
Benefits of early initiation may extend beyond mortality
alone to decreased co-infections, decreased resource costs
and possibly even prevention efforts [23].Acknowledgements
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